The domestic cat is the most susceptible host to Sporothrix infection, developing severe clinical forms. Few effective antifungal agents are available for treating feline sporotrichosis, and cases of treatment failure are common. Treatment success depends on cat health status, therapy-related factors, as well as social/economic issues, but it is mainly contingent upon the host–fungus interaction. The owner's adherence is critical and should be reinforced throughout the treatment to increase the chances of a successful outcome. The antifungal agents described for feline sporotrichosis are most often used in monotherapy regimens. Due to cases in which the treatment with itraconazole failed, the use of antifungal agents in combination should be considered to achieve synergy. The combination of itraconazole and potassium iodide represents an important option for the treatment of naïve cats presenting multiple cutaneous lesions, nasal mucosal lesions and/or respiratory signs, as well as for refractory cases. However, the therapeutic options for unsuccessfully treated cases are scarce. Therefore new options are needed, even more taking into account that there are many in vitro potential molecules not available for use in cats yet. More studies are necessary to correlate in vitro antifungal susceptibility tests results and the outcome of cats treated due to sporotrichosis. This review will briefly discuss both the antifungal drugs and treatment protocols used in cats with sporotrichosis, as well as the determinants of treatment failure.

家猫是孢子丝菌最易感的宿主感染，发展为严重的临床形式。很少有有效的抗真菌药物可用于治疗猫孢子丝菌病，并且治疗失败的情况很常见。治疗成功取决于猫的健康状况、治疗相关因素以及社会/经济问题，但主要取决于宿主与真菌的相互作用。主人的坚持是至关重要的，应该在整个治疗过程中得到加强，以增加成功结果的机会。描述的用于猫孢子丝菌病的抗真菌剂最常用于单一疗法。由于伊曲康唑治疗失败的病例，应考虑联合使用抗真菌药物以达到协同作用。伊曲康唑和碘化钾的组合是治疗幼稚症的重要选择表现出多处皮肤损伤、鼻粘膜损伤和/或呼吸道症状的猫，以及难治性病例。然而，治疗失败病例的治疗选择很少。因此需要新的选择，更要考虑到有许多体外潜在分子尚不能用于猫。需要更多的研究来将体外抗真菌药敏试验结果与因孢子丝菌病治疗的猫的结果相关联。本综述将简要讨论用于猫孢子丝菌病的抗真菌药物和治疗方案，以及治疗失败的决定因素。